HIMS Stock Recent News

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and women's health, dermatology, and mental health, along with its personalized healthcare solutions, supports long-term growth potential. Strong financial performance with a 69% revenue increase in 2024, a growing subscriber base, and improved marketing efficiency highlight H&H's disciplined growth strategy.

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Hims & Hers Health has become one of the most popular growth stocks in the market today. After sharing with my readers a bullish perspective on the stock at ~$6/share in 2023, I'm back to provide a unique perspective that sheds light on what the platform does. In short, I like to call Hims an "AI-orchestrated general physician at national scale," and I'll walk us through what that means today.

Hims & Hers Health, Inc. stock surged to $68, and the subsequent 50% crash is the talk of the town. I'm eyeing it as a favorable high-risk, high-reward play. HIMS stock plummeted after the FDA halted approval of its top-selling GLP-1 weight loss drug, which is priced at $165 and offers the same as Ozempic, priced on average $1,000. The FDA's pending decision on semaglutide's shortage status, due April 22nd, is crucial; a favorable ruling could boost HIMS stock significantly.

Hims & Hers (HIMS) is a newfangled tele-health company that started to ride the waves of GLP-1 weight loss medications. As waves go, this one's given the stock a heck of ride; way up and then all the way back down. More big moves could happen in the near term. Looking deeper and reading a lot of tea leaves, I envision HIMS growing from a peddler of feel-good non-essential medications into a serious player in the emerging personalized medicine field.

Hims & Hers Health (HIMS -6.95%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target on the pharmaceuticals stock in the worst way possible.

Hims & Hers Health (HIMS 3.58%) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach delivered some good news for the mail-order drugs stock.

MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs introduces RKLX and HIMZ, two 2X leveraged single-stock ETFs designed to provide amplified exposure to Rocket Lab USA, Inc. (NASDAQ: RKLB) and Hims & Hers Health Inc. (NYSE: HIMS). These ETFs offer traders a way to seek enhanced returns on Rocket Lab and Hims & Hers without requiring a margin account.

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $34.71, marking a +0.7% move from the previous day.